PLX-200

DRUG2 trials

Sponsors

Polaryx Therapeutics, Inc.

Conditions

CLN2CLN3Juvenile Neuronal Ceroid LipofuscinosisKrabbe DiseaseLysosomal Storage DisordersSandhoff Disease

Phase 2

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)

Not yet recruitingNCT07740512

Polaryx Therapeutics, Inc.CLN2, CLN3, Krabbe Disease +2

Start: 2026-12-01End: 2029-02-01Target: 24Updated: 2026-07-31

Phase 3

Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3

WithdrawnNCT04637282

Polaryx Therapeutics, Inc.Juvenile Neuronal Ceroid Lipofuscinosis

Start: 2026-11-01End: 2026-12-31Updated: 2026-08-19